Vibrational Microspectroscopy for Cancer Screening by Lyng, Fiona et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles DIT Biophotonics and Imaging 
2015-3 
Vibrational Microspectroscopy for Cancer Screening 
Fiona Lyng 
Technological University Dublin, Fiona.lyng@tudublin.ie 
Ines Ramos 
Technological University Dublin 
Ola Ibrahim 
Technological University Dublin 
Hugh Byrne 
Technological University Dublin, hugh.byrne@tudublin.ie 
Follow this and additional works at: https://arrow.tudublin.ie/biophonart 
 Part of the Biological and Chemical Physics Commons, Diagnosis Commons, and the Other Analytical, 
Diagnostic and Therapeutic Techniques and Equipment Commons 
Recommended Citation 
Lyng, F. et al. (2015) Vibrational Microspectroscopy for Cancer Screening, Applied Sciences, 5, 23-35 
(2015) 
This Article is brought to you for free and open access by 
the DIT Biophotonics and Imaging at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
 Appl. Sci. 2015, 5, 23-35; doi:10.3390/app5010023 
 
applied sciences 
ISSN 2076-3417 
www.mdpi.com/journal/applsci 
Review 
Vibrational Microspectroscopy for Cancer Screening 
Fiona M. Lyng 1,2,*, Inês R. M. Ramos 1,2, Ola Ibrahim 1,2 and Hugh J. Byrne 3 
1 DIT Centre for Radiation and Environmental Science, FOCAS Research Institute,  
Dublin Institute of Technology, Kevin St, Dublin 8, Ireland;  
E-Mails: d11127684@mydit.ie (I.R.M.R.); ola.ibrahim@mydit.ie (O.I.) 
2 School of Physics, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland 
3 FOCAS Research Institute, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland;  
E-Mail: hugh.byrne@dit.ie 
* Author to whom correspondence should be addressed; E-Mail: fiona.lyng@dit.ie;  
Tel.: +353-1-402-7972; Fax: +353-1-402-7901. 
Academic Editor: Ken Ledingham 
Received: 7 December 2014 / Accepted: 10 February 2015 / Published: 13 February 2015 
 
Abstract: Vibrational spectroscopy analyses vibrations within a molecule and can be  
used to characterise a molecular structure. Raman spectroscopy is one of the vibrational 
spectroscopic techniques, in which incident radiation is used to induce vibrations in the 
molecules of a sample, and the scattered radiation may be used to characterise the sample 
in a rapid and non-destructive manner. Infrared (IR) spectroscopy is a complementary 
vibrational spectroscopic technique based on the absorption of IR radiation by the sample. 
Molecules absorb specific frequencies of the incident light which are characteristic of their 
structure. IR and Raman spectroscopy are sensitive to subtle biochemical changes occurring 
at the molecular level allowing spectral variations corresponding to disease onset to be 
detected. Over the past 15 years, there have been numerous reports demonstrating the 
potential of IR and Raman spectroscopy together with multivariate statistical analysis 
techniques for the detection of a variety of cancers including, breast, lung, brain, colon, 
oral, oesophageal, prostate and cervical cancer. This paper discusses the recent advances 
and the future perspectives in relation to cancer screening applications, focussing on cervical 
and oral cancer. 
Keywords: optical diagnosis; lasers; Raman spectroscopy; FTIR spectroscopy;  
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1. Introduction 
Cancer is a leading cause of disease worldwide with 14.1 million new cases, 8.2 million cancer 
deaths and 32.6 million people living with cancer (within five years of diagnosis) in 2012 [1].  
Many cancers develop through pre-malignant stages which allow screening programmes to be 
implemented to detect cellular changes before invasive cancer develops. A good example is cervical 
cancer screening using the Papanicolaou (Pap) test which involves microscopic examination of cells 
exfoliated from the cervix. 
Cytology is the study of disease at the cellular level and involves the preservation, staining and 
microscopic examination of cells that have been extracted from the body. Cytology can be used for 
practically any tissue type to detect abnormal cells. The principle of cytology is based on the fact that 
cancer cells lose their adhesive properties early in the disease process and can thus be easily exfoliated 
from tissue. An advantage of cytology is that sample collection is generally simple, rapid and painless. 
Cytological screening aims to detect pre-cancer and cancer in a healthy population. In such 
populations, disease prevalence is relatively low and achieving a high test sensitivity is critical  
(see Figure 1). The aim of screening is to correctly identify as many cases of disease (positives)  
as possible while minimising incorrect identification of disease in individuals who do not have the 
disease (false positives) and negatives in individuals who do have the disease (false negatives). A false 
positive would result in a patient possibly undergoing unnecessary treatment while a false negative 
would result in a patient remaining undiagnosed and possibly progressing to cancer.  
There is an unmet clinical need for new methods to aid cytologists in the early detection of  
pre-cancer. These methods ideally should be rapid, non-destructive, require minimal sample preparation 
and mostly importantly should not be subjective. 
 
Figure 1. Definition of sensitivity and specificity. 
2. Vibrational Spectroscopy 
Vibrational spectroscopy analyses vibrations within a molecule and the spectrum of vibrational 
energies or frequencies (in wavenumbers, cm−1) can be used to characterise a molecular structure. 
Every molecule has a unique spectrum which allows identification of the molecular compound and its 
abundance in a sample [2].  
Sensitivity
• a measure of the ability of the 
screening test to identify 
positives 
• expressed as the percentage of 
positives correctly identified 
by the test out of the total 
number of positives actually 
tested
Specificity
• a measure of the ability of the 
screening test to identify 
negatives 
• expressed as the percentage of 
negatives correctly identified 
by the test out of the total 
number of negatives actually 
tested
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The exact energy required to excite a molecular vibration depends on the masses of the atoms 
involved in the vibration and the type of chemical bonds between these atoms and may be influenced 
by molecular structure, molecular interactions and the chemical microenvironment of the molecule. 
Vibrational energies fall within the mid Infrared (IR) region of the electromagnetic spectrum and 
are commonly probed using IR absorption spectroscopy. IR spectroscopy is based on the absorption of 
infrared radiation by the sample and the fact that molecules absorb specific frequencies of the incident 
light which are characteristic of their structure.  
A typical cellular FTIR spectrum is shown in Figure 2, together with a list of tentative spectral 
assignments in Table 1 [3]. The spectrum shown in Figure 2 can be divided into two regions, the high 
wavenumber region from 2500–4000 cm−1, corresponding to absorptions due to O-H, N-H, C-H 
stretching vibrations, and the fingerprint region from 900–1800 cm−1, which consists of many 
overlapping bands (see Table 1), and is characteristic of the sample.  
 
Figure 2. Typical FTIR spectrum from a population of cells. 
Table 1. Tentative peak assignments [3] for typical FTIR cellular spectrum shown in Figure 2. 
Wavenumber (cm−1) FTIR Peak Assignments 
1036 C-C skeletal stretching (proteins) 
1080 PO2 symmetric stretching (DNA/RNA) 
1150 C-C and C-O stretching (proteins) 
1220–1280 PO2 asymmetric stretching (DNA/RNA), Amide III (C-N stretching, N-H bending, proteins)
1310 CH2 stretching (phospholipids) 
1450–1470 CH3 asymmetric stretching (proteins, lipids) 
1520–1550 Amide II (N-H bending, C-N stretching, proteins) 
1620–1700 Amide I (C=O stretching, C-N stretching and N-H bending, proteins) 
2850 CH2 symmetric stretching (lipids) 
2920 CH2 asymmetric stretching (lipids) 
2960 CH3 asymmetric stretching (lipids and proteins) 
3290 NH asymmetric stretching (proteins) 
3400 OH stretching (water) 
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Raman spectroscopy is an optical method based on inelastic light scattering. The sample is illuminated 
by monochromatic laser light and interactions between the incident photons and molecules in the 
sample result in scattering of the light. The coupling of the light generates vibrations within the 
material, which are again characteristic of the chemical structure, and the energy of the scattered light 
is reduced by an amount equal to the energy of the vibrational energy. Thus, the positions, relative 
intensities and shapes of the bands in a Raman spectrum carry detailed information about the molecular 
composition of the sample.  
A typical cellular Raman spectrum is shown in Figure 3, together with a list of tentative spectral 
assignments in Table 2 [4]. As for Figure 2, the spectrum can be divided into two regions, the high 
wavenumber region, from 2500–3500 cm−1, and the fingerprint region, from 400–1800 cm−1. 
 
Figure 3. Typical cellular Raman spectrum. 
Table 2. Tentative peak assignments [4] for typical Raman cellular spectrum shown in Figure 3. 
Wavenumber (cm−1) Raman Peak Assignments 
621 C-C twisting mode of Phenylalanine (proteins) 
642 C-C twisting mode of Tyrosine and Phenylalanine 
670 Thymine, Guanine (DNA/RNA) 
720 C-N stretching in Adenine and lipids 
750 symmetric breathing of Tryptophan (protein) 
782 Uracil, Thymine, Cytosine (ring breathing modes in the DNA/RNA) 
827 PO2 stretching in DNA, Tyrosine 
854 Ring breathing in Tyrosine and Proline (proteins) 
935 C-C stretching mode of Proline and Valine 
1003 C-C aromatic ring stretching in Phenylalanine 
1030 C-H bending mode in Phenylalanine, C-N stretching in proteins 
1080 PO2 symmetric stretching (DNA/RNA) 
1085 C-O stretching 
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Table 2. Cont. 
Wavenumber (cm−1) Raman Peak Assignments 
1130 C-N stretching in proteins; C-O stretching in carbohydrates 
1155 C-C and C-N stretching of proteins/lipids 
1175 C-H in plane bending mode of Tyrosine and Phenylalanine; Cytosine, Guanine 
1208 C-C6H5 stretching mode in Tryptophan, Phenylalanine 
1220–1280 Amide III (C-N stretching, N-H bending, proteins), PO2 asymmetric stretching (DNA/RNA)
1311 CH3/CH2 twisting mode of collagen and lipid 
1340 Guanine (DNA/RNA), CH def. in proteins and carbohydrates 
1430–1460 CH (CH2) bending mode in proteins and lipids 
1485 Amide II (N-H bending, C-N stretching, proteins); Adenine, Guanine (DNA/RNA) 
1580 Adenine, Guanine (DNA/RNA); C=C bending mode of Phenylalanine 
1615 C=C Phenylalanine, Tyrosine and Tryptophan 
1620–1700 Amide I (C=O stretching, C-N stretching and N-H bending, proteins) 
2890 CH2 symmetric stretching (lipids) 
2940 CH2 and CH3 symmetric stretching (lipids) 
2980 CH3 symmetric stretching (lipids) 
Raman and IR spectroscopy are complementary techniques. IR spectroscopy involves the absorption 
of radiation whereas Raman spectroscopy is a scattering technique, whereby the incident radiation 
couples with the vibrating polarisation of the molecule and generates or annihilates a vibration. These 
different underlying mechanisms give rise to the complementarity of the two techniques and they each 
have different selection rules. For a vibration to be active in IR spectroscopy, a change in dipole is 
required, whereas a change in polarisability is required for a vibration to be Raman active. Vibrations 
of asymmetric, polar bonds tend to be strong in IR spectra, whereas symmetric, nonpolar groups are 
strong in Raman spectra. For example, O-H vibrations of water are very strong in IR spectra, whereas 
they are relatively weak in Raman spectra. This feature means that Raman spectroscopy may be a more 
suitable technique for biological applications. Another difference is that Raman spectroscopy can be 
employed in the UV, visible or near IR regions of the electromagnetic spectrum whereas IR spectroscopy 
monitors the absorption of IR radiation. Therefore, Raman spectroscopy has a higher spatial resolution 
(<1 µm for Raman, ~5–10 µm for IR). Raman spectroscopy is, however, inherently weak with only a small 
percentage of photons undergoing Raman scattering (~10−6). Longer spectral acquisition times are 
therefore needed to achieve adequate signal to noise in Raman compared to IR spectroscopy. 
IR and Raman spectra of biomedical samples such as cells and tissues are a superposition of all the 
contributions from each individual biochemical component such as DNA, RNA, proteins, lipids and 
carbohydrates. Thus vibrational spectroscopy methods can provide a molecular diagnosis by providing 
a “biochemical fingerprint” of the complete genome, proteome and metabolome of the cell or tissue [5]. 
This can be provided in a rapid, label free, non-destructive manner allowing additional analyses to be 
performed subsequently, such as staining, immunocytochemistry etc. Standardised methods and procedures 
for collecting IR spectra and images from biological samples have recently been described [6]. 
In recent years, Raman and FTIR spectroscopy have been used in the detection of a variety of 
cancers, including breast, prostate, oesophageal, colon, lung, oral and cervical cancer, and excellent 
sensitivity and specificity values have been reported [7–9].  
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For the purposes of this review, cervical and oral cancers will be focussed on as these tissues are 
readily accessible and amenable to cytological screening.  
3. Cervical Cancer 
Cervical cancer is the fourth most common cancer in women worldwide with an estimated 528,000 
new cases and 266,000 deaths in 2012 [1]. The mortality associated with cervical cancer can be reduced 
if this disease is detected at the early stages of development or at the pre-malignant state (cervical 
intraepithelial neoplasia, CIN).  
Currently, a Papanicolaou test is used to screen for CIN and cervical cancer in the general female 
population. The Papanicolaou test (also called Pap smear, Pap test, cervical smear, or smear test) is  
a screening test used to detect cancer and pre-cancer in the ectocervix. A spatula or cytobrush is used 
to collect the cells from the cervix and after placing in liquid fixative, the cells are then collected on  
a filter and transferred to a slide and stained. The cells are examined for abnormalities under the 
microscope by highly trained personnel. The Pap test is an effective, widely used method for early 
detection of cervical cancer and pre-cancer. Despite a high specificity of 95%–98%, the sensitivity of 
the Pap test is reported to vary greatly from 74% to 96% [10]. Low grade dysplasia or CIN 1 can 
spontaneously regress without leading to cervical cancer. However some CIN 1 lesions progress to 
moderate (CIN 2) and subsequently severe dysplasia (CIN 3), finally progressing to invasive cancer [11]. 
An abnormal Pap smear is followed by colposcopy, biopsy and histological confirmation of the diagnosis. 
This involves the visual examination of histological sections by highly trained personnel. The grading 
characteristics are quite subjective and pre-malignancy may not be visually perceptible at all.  
Persistent infection with high-risk human papillomavirus (HPV) (e.g., HPV types 16, 18) is accepted 
as the major cause for the development of cervical pre-cancer and cancer [12]. HPV testing has 
recently been introduced in parallel with Pap smear screening for safe and cost-effective lengthening 
of the cervical screening interval due to its high-negative predictive values [13]. The HPV DNA test 
identifies high-risk HPV oncogene expression. However, this test is expensive, time-consuming and 
requires experienced technicians. Over the last decade, prophylactic HPV vaccines have been developed 
but despite the introduction of these vaccines, there is still a need for regular cervical screening, as the 
vaccines do not protect against all oncogenic HPV types. Additionally, some women may not benefit 
from the vaccines if there is a pre-existing HPV infection or they do not receive the complete number 
of doses (three doses over a 6-month period). After vaccination, women must still get routine Pap tests 
which can detect abnormal cervical growth regardless of what HPV type causes it to develop.  
The first investigations of cervical exfoliated cells using IR spectroscopy were in the early 1990’s 
by Wong and co-workers. They published a number of papers showing significant differences between 
normal, pre-cancer and cancer samples [14–17].  
These initial studies recorded spectra from cell pellets rather than from individual cells and a number 
of confounding factors such as polymorphs, endocervical columnar cells, metaplastic cells, cervical 
mucus and debris were subsequently identified [18]. Further investigations by other groups identified 
similar confounding factors such as inflammation, metaplasia, hormonal changes, metabolic activity, 
blood, mucus [19–23].  
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However, an important early study by Cohenford and Rigas [24] showed that the FTIR spectra of 
morphologically normal exfoliated cells from women with dysplasia or cancer exhibit extensive IR 
spectroscopic changes. This finding was later confirmed by Schubert et al. [25] who showed spectral 
changes in cytologically normal cells, most likely due to HPV infection. 
Walsh et al. [26] employed attenuated total reflection (ATR) FTIR spectroscopy to show spectral 
differences between normal and low grade and high grade dysplasia cytology samples. ATR-FTIR 
spectroscopy involves the IR beam being directed through a high refractive index crystal, typically 
diamond, germanium or zinc, where it undergoes total internal reflection generating an evanescent 
waveform that interacts with the biological sample at the surface of the crystal. Interestingly, a recent 
ATR—FTIR study has shown that cervical pre-cancer is more accurately identified when histology 
rather than cytology is used as the gold standard to classify the samples [27]. 
ATR-FTIR spectroscopy has also been shown to be capable of distinguishing between high risk 
HPV infections in women with low grade and high grade dysplasia [28]. Interestingly, spectral differences 
were also found between women in their 20s and in their 30s in samples of the same cytological grade 
and HPV type, most likely because of a persistent HPV infection. Schubert et al. [25] also showed that 
FTIR spectroscopy could discriminate cervical exfoliated cells based on their HPV status. In addition, 
a number of studies have used cervical cell lines as model systems to show the ability of vibrational 
spectroscopy (both IR and Raman) to differentiate cells based on HPV status [28–33]. 
In contrast to the extensive work on exfoliated cervical cells using IR spectroscopy, there are relatively 
few studies using Raman spectroscopy, most likely because of the issues with confounding factors.  
Vargis et al. [33] showed that Raman spectroscopy could classify HPV-positive and -negative cytology 
samples with an accuracy of 98.5%. A study by Rubina et al. [34] used Raman spectroscopy to distinguish 
between normal and cervical cancer cytology samples. As the spectra of cervical cancer samples were 
dominated by blood features, cytology samples were treated with red blood cell lysis buffer prior to 
Raman acquisition. A classification accuracy of ~80% was obtained. Both of these studies used cell 
pellets rather than recording Raman spectra from individual cells and this probably resulted in the 
relatively low classification accuracy in the study by Rubina et al. due to sample heterogeneity. 
A recent study by Bonnier et al. [35] addressed many of the issues involved in recording Raman 
spectra from ThinPrep cervical cytology samples. A new method based on pre-treatment of the slides 
with hydrogen peroxide to clear blood residue contamination before Raman recording was shown to 
minimise variability within the data sets. This resulted in the collection of highly reproducible data 
with clear discrimination between negative cytology and CIN cytology. Importantly, all data was recorded 
on glass ThinPrep slides which are currently used for clinical cervical cytology rather than spectroscopic 
substrates such as MirrIR or calcium fluoride substrates which are commonly used for research purposes 
and, although they reduce the presence of confounding contributions of the substrate, are considerably 
more expensive. 
4. Oral Cancer 
Oral cancer is defined as squamous cell carcinoma of the lip, oral cavity and oropharynx, and is the 
sixth most common malignancy in the world [36]. Patients with oral squamous cell carcinoma (OSCC) 
often have a poor outcome even though advances in treatment have been made. The 5 year survival 
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rate is approximately 80% for early stage disease but only approximately 20% for late stage disease [37] 
and patients often present with advanced disease. Multiple primary tumours are common and second 
primary tumours are the most common cause of death in patients with early stage disease [38]. 
OSCC is a multi causal disease and risk factors include lifestyle habits (tobacco exposure and alcohol 
consumption), dietary factors, occupational activity, socioeconomic status, exposure to external agents, 
and genetic susceptibility [39,40]. Most cases of oral cancer occur in patients of 60 years or over and 
the risk increases with advancing age.  
The gold standard method for diagnosis of oral cancer and pre-malignant lesions is clinical examination 
and histopathological evaluation of biopsied tissue [41]. Conventional visual and tactile examination 
(CVTE) is used to detect OSCC and pre-malignant oral lesions in a screening setting but oral  
pre-malignant lesions and some early OSCC can be difficult to distinguish from inflammatory lesions. 
Most lesions are white patches known as leukoplakia and only approx. 4% of these lesions progress to 
cancer. CVTE cannot distinguish between these lesions and non-progressive lesions. Biopsy is followed 
by histopathology, where the excised tissue is processed, cut into sections and mounted on a glass slide 
for examination by a pathologist. Grading of tumours depends on the visual assessment of tissue 
architecture and characteristics of individual cells. The grading characteristics used are highly subjective 
and early proliferation/pre-malignancy may not be apparent morphologically. In addition, it can be 
difficult to discriminate between reactive/inflammatory lesions and pre-cancer lesions. 
A number of screening and diagnostic aids for early detection and diagnosis of oral cancer and  
pre-cancer have become available over the last decade including brush biopsy, toluidine blue vital 
staining, post-acetic acid rinse tissue reflectance and tissue autofluorescence. Some of these techniques 
show promise but as yet none has been definitively proven to perform better than conventional visual 
examination [42]. Well designed clinical studies are needed where the techniques are directly compared 
to the diagnostic gold standard, scalpel biopsy and histopathology. 
Early detection of cancer greatly increases the chances for successful treatment. There is a significant 
clinical need for new techniques that can detect pre-malignant changes that may progress to cancer. Oral 
cancer progression is not as clear cut as, for example, in cervical cancer in which there is a well-defined 
progression from mild to moderate to severe dysplasia (CIN 1, 2 and 3). The majority of histologically 
pre-malignant oral lesions do not progress to cancer at all and mild dysplasia can progress to cancer as 
readily as severe dysplasia. In a long term follow up of 236 patients with oral lesions, Holmstrup et al. [43] 
found that the degree of dysplasia was not a predictor of malignant potential of the lesions. The 
inability of conventional histopathology to predict which lesions will progress to cancer underlines the 
need for new techniques or new technologies to address this clinical need. 
While a number of Raman spectroscopy studies have been carried out on oral tissues [44–46],  
to date, only a limited number of IR studies have focused on oral exfoliated cells.  
Papamarkakis et al. [47] showed that oral cells could be classified according to anatomical region 
with cells from cheek, palate and gums being spectrally similar whereas cells from the tongue and from 
the floor of the mouth were spectrally distinct due to an abundance of keratin and collagen respectively. 
It was further shown that samples from patients with reactive atypical changes or malignancy associated 
changes were more spectrally similar to a sample from a patient with squamous cell carcinoma than to 
samples from healthy volunteers [47]. A further IR study from the same group [5,48] showed that 
spectra from squamous cells collected from the tongues of healthy volunteers could be discriminated 
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from squamous cells collected from the tongues of patients with oral disease, mostly dysplastic and 
cancer cases, using unsupervised principal components analysis. An artificial neural network was 
trained to automatically distinguish the clinical cases from the normal cases and sensitivity and 
specificity values of 96% and 94.3% were obtained. Interestingly, these results were obtained from 
morphologically normal cells, the majority of cells present in exfoliated cell samples. This indicates 
that biochemical changes can be detected by IR spectroscopy before morphological changes are apparent. 
5. Future Perspectives 
Vibrational spectroscopy shows great potential as a label free, high sensitivity and specificity test for 
cervical and oral cancer screening. The respective techniques of Raman and IR spectroscopy each has 
its own potential advantages for clinical applications (reviewed in [49]), with Raman spectroscopy 
having a higher spatial resolution, minimal sample preparation, and minimal interference from water and 
FTIR spectroscopy having a higher signal to noise ratio allowing faster acquisition times. ATR-FTIR 
spectroscopy can achieve higher spatial resolution and can allow measurement from aqueous samples. 
Recent advances in these techniques have included surface enhanced Raman spectroscopy (SERS), 
which allows significant enhancement of the Raman signal through close proximity/adsorption onto  
a roughened metal surface, a colloidal solution or a roughened electrode, tip enhanced Raman spectroscopy 
(TERS) which combines the high spatial resolution of atomic force microscopy with SERS, coherent 
anti-Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS) (reviewed in [50]) 
which allow rapid real time imaging of single cells, and the development of high brightness quantum 
cascade lasers to improve acquisition times for IR imaging. For cytology applications, a key consideration 
is that these spectroscopic techniques could fit into the current workflow. Both Raman and IR 
spectroscopy can be operated in microscopic mode and, with automated spectral acquisition, these 
techniques could be similar to the Thinprep Imager (Hologic) or the Focal Point GS Imaging system 
(BD), which use image processing algorithms to automatically review liquid based cytology Thinprep 
and SurePath slides. Both Raman and IR spectroscopy are reagent free, so costs should be favourable 
when compared to the imaging systems or to manual scoring where personnel costs could be reduced. 
A recent study [35] has shown that glass ThinPrep slides can be used for Raman spectral recording 
whereas spectroscopic substrates, such as MirrIR or calcium fluoride substrates, are used for IR 
spectroscopy and although they reduce the presence of confounding contributions of the substrate,  
they are considerably more expensive than the glass slides used in the cytology laboratory. 
However, much work still remains before these techniques could be translated into standard clinical 
practice [51]. Many studies have used relatively small sample sizes and as such may be biased. 
Screening populations are heavily weighted towards negative results with only a small percentage of 
positive results so validation in large multi centre studies is needed using real world cytology samples 
from screening populations. Large scale clinical trials are needed to obtain the large volumes of data 
necessary for the development of robust classification algorithms and histopathology rather than 
cytology should be used to classify the samples.  
If spectroscopy can be shown to be as good as, or better than, the gold standard histopathology,  
then there is great potential for these techniques to be used as an alternative or an adjunct to the  
current cytology screening methods. The advantages would be higher accuracy, higher throughput  
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and reduced workload for the cytologist/pathologist and higher accuracy and chance of earlier 
detection for the patient. 
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